Previous adjusted EBITDA guidance was $108.0M-113.0M. Raises FY25 Modern Orals sales view to $100.0-$110.0M from $80.0M-95.0M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TPB:
- Avis Budget downgraded, Sprouts upgraded: Wall Street’s top analyst calls
- Turning Point Brands initiated with a Hold at Needham
- Turning Point Brands: Promising Growth in Nicotine Pouches and Diverse Revenue Streams, But Current Valuation Justifies Hold Rating
- FRE Nicotine Pouches partners with PBR for ‘Unleash The Beast’